宣武医院团队发现血管生成素2（ANGPT2）促进散发脑动静脉畸形进展,血管,畸形,生成素,病灶,周细胞,脑血管 ...

首都医科大学宣武医院神经外科洪韬、张鸿祺教授团队，在血管机制研究知名期刊《Angiogenesis》杂志上发表了题为 “Inhibition of Angiopoietin‑2 rescues sporadic brain arteriovenous ...

北京宣武医院的研究团队近日在国际知名期刊《Angiogenesis》上发表了一项重要研究，揭示了血管生成素2（ANGPT2）在促进散发性脑动静脉畸形（BAVM）进展方面的重要作用。此种先天性神经血管疾病是导致青少年出血性卒中的一大元凶，现有的外科治疗方法往往会损伤周围正常脑组织，从而使临床需求愈加迫切。

▎药明康德内容团队编辑转移性结直肠癌（mCRC）患者中约8%~15%存在BRAF基因突变，BRAFV600E是最常见的突变形式之一。BRAFV600E突变型的mCRC患者预后差、总生存期短。Encorafenib是一种高选择性的ATP竞争性小分子BR ...

Pfizer received accelerated approval from the FDA for its Braftovi combo regimen to treat treatment-naïve patients with BRAFV600E-mutant mCRC. The approval was based on a clinically meaningful ...

Chemoradiotherapy (CRT) followed by sequential tislelizumab (TIS) + CAPOX and TIS monotherapy for organ preservation in locally advanced low rectal cancer. A phase 2, multicenter, open-label study of ...

Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies. This is an ASCO ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ...

Cancer-associated fibroblasts (CAF) generate an extracellular matrix (ECM) which provides a repository for factors that promote pancreatic cancer progression. In this study, we establish that CAF ...

Prior to the FDA approval of BRAF/MEK combination therapy, Children’s Healthcare of Atlanta had used monotherapy BRAFi off-study in patients with many BRAFV600E mutated pLGGs. Several early phase ...

Cyclooxygenases-2 (COX-2) and Prostaglandin E2 (PGE2), which are important in chronic inflammatory diseases, can increase tumor incidence and promote tumor growth and metastasis. PGE2 binds to various ...

Dekker C. Deacon, MD, PhD completed his residency in dermatology at the University of Utah and has a special interest in the genetics of skin cancer and skin cancer treatment, including Basal Cell ...